References
- Zimmerman B G. Adrenergic facilitation by angiotensin: does it serve a physiological function? Clin. Science 1981; 60: 343–348
- Unger T, Ganten D, Lang R E. Converting enzyme inhibitors: antihypertensive drugs with unexpected mechanisms. TIPS 1983; 4: 514–519
- Stamler J F, Brody M J, Phillips M I. The central and peripheral effects of captopril (SQ 14225) on the arterial pressure of the spontaneously hypertensive rat. Brain Res 1980; 186: 499–503
- Unger T, Kaufmann-Bühler I, Schölkens B, Ganten D. Brain converting enzyme inhibition: a possible mechanism for the antihypertensive action of captopril in spontaneously hypertensive rats. Eur. J. Pharmacol 1981; 70: 467–478
- Farnebo L O, Hamberger B. Drug-induced changes in the release of 3H-monoamines from field-stimulated rat brain slices. Acta physiol. Scand 1971; 371(Suppl.)35–44
- Schacht U, Leven M, Bäcker G. Studies on brain metabolism of biogenic amines. Brit. J. clin. Pharmac 1977; 4: 77S–87S
- ScHölkens B, Becker R, Unger T, Linz W. Antihypertensive activity of a novel orally active non-sulfhydryl converting enzyme inhibitor HOE 498. N.-S. Arch. Pharmacol 1983; 324(Suppl.)R 42
- Witte P U, Metzger H, Irmisch R. Pharmacodynamics of HOE 498 (ACE inhibitor) in healthy volunteers. N.-S. Arch. Pharmacol 1983; 324(Suppl.)R75
- Phillips M I. New evidence for brain angiotensin and for its role in hypertension. Federation Proc 1983; 42: 2667–2672